Cancer-associated venous thrombosis is a common condition, although the reported
incidence varies widely between studies depending on patient population, start and duration …

Long-term survival rates after a diagnosis of breast cancer are steadily rising. This is good
news, but clinicians must also recognize that this brings new challenges to the medical …

2.1. 1. Epidemiology and burden of the disease. The annual incidence of first episode of
symptomatic DVT in the adult population ranges from 50 to 100 per 100 000 population, with …

Background The post-thrombotic syndrome frequently develops in patients with proximal
deep-vein thrombosis despite treatment with anticoagulant therapy. Pharmacomechanical …

Background Although many patients with venous thromboembolism require extended
treatment, it is uncertain whether it is better to use full-or lower-intensity anticoagulation …

Background We update recommendations on 12 topics that were in the 9th edition of these
guidelines, and address 3 new topics. Methods We generate strong (Grade 1) and weak …

Background Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin
in patients with venous thromboembolism is unclear. Methods In a randomized, double …

Background This article addresses the treatment of VTE disease. Methods We generated
strong (Grade 1) and weak (Grade 2) recommendations based on high-quality (Grade A) …

Methods Members of the writing panel were invited by the American Heart Association
Scientific Council leadership because of their multidisciplinary expertise in PTS. Writing …

Background Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose
regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without …